This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cosmetic Surgery Stocks Keep Stiff Upper Lip

The share moves of companies that practice aesthetic medicine have been downright ugly in the past year.

Over the last 12 months, the providers of breast implants, anti-wrinkle products and liposuction equipment have traded below the Amex Pharmaceutical index of large drug companies.

Allergan (AGN - Get Report) was down 35%, Mentor (MNT) was off 63%, and Medicis Pharmaceutical (MRX) was down 54% for the 12 months ended Oct. 21.

The Amex index was off 23% for this period, while the S&P 500 was down nearly 37%.

Although each company has a unique set of circumstances, the common theme for their sagging stocks is the economy. Because many of their products and treatments don't receive insurance coverage, their share prices have declined with consumers' decisions to postpone or delay personal makeovers.

"Some portions of their businesses are exposed to discretionary consumer spending, and the economy affects products differently," says Jeff Viksjo of the independent financial research firm Morningstar.

When the economy skids, he says, people will postpone cosmetic breast implant surgery. Also, customers may take longer than usual in seeking the next in a series of planned Botox injections, Viksjo adds.

Despite drooping stock prices, some analysts say these companies have been beaten down so much that an improving economy should augment their shares.

Viksjo gives five-star ratings to Mentor and Medicis, meaning he believes their stocks are trading below their fundamental strengths. Allergan gets four stars on the five-star scale.

Mentor is the most dependent on products lacking insurance coverage. Roughly 89% of its revenue comes from breast implants, based on the fiscal quarter that ended June 27. Second-quarter results will be announced Nov. 5. "Mentor has a solid balance sheet, and it presents a very compelling case for investors willing to ride out the bumps," says Viksjo.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRX $0.00 0.00%
AGN $322.49 2.74%
AAPL $117.34 -0.81%
FB $107.12 2.76%
GOOG $767.04 3.29%


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs